IGFBP-1(Insulin-like growth factor binding protein 1) antibody/antigen (BSA/OVA/KLH conjugated hapten)

anti-IGFBP-1(Insulin-like growth factor binding protein 1) antibody and Carrier-coupled antigen/immunogen (hapten-carrier conjugates)

Target products collectionGo to Hormones diagnostics products collection >>


Product information

Catalog No.DescriptionUS $ Price (per mg)
GMP-SMT-196-11. BSA-IGFBP-1(Insulin-like growth factor binding protein 1)
2. Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody
$2709.00
GMP-SMT-196-21. OVA-IGFBP-1(Insulin-like growth factor binding protein 1)
2. Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody
$2709.00
GMP-SMT-196-31. BSA-IGFBP-1(Insulin-like growth factor binding protein 1)
2. Anti-IGFBP-1(Insulin-like growth factor binding protein 1) human monoclonal antibody
$2709.00
GMP-SMT-196-41. OVA-IGFBP-1(Insulin-like growth factor binding protein 1)
2. Anti-IGFBP-1(Insulin-like growth factor binding protein 1) human monoclonal antibody
$2709.00
GMP-SMT-196-Ag-1BSA-IGFBP-1(Insulin-like growth factor binding protein 1)$756.00
GMP-SMT-196-Ag-2OVA-IGFBP-1(Insulin-like growth factor binding protein 1)$756.00
GMP-SMT-196-Ab-1Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody$1953.00
GMP-SMT-196-Ab-2Anti-IGFBP-1(Insulin-like growth factor binding protein 1) human monoclonal antibody$1953.00

Size: 1mg | 10mg | 100mg



Product Description


BSA-IGFBP-1(Insulin-like growth factor binding protein 1)

Cat No.GMP-SMT-196-Ag-1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates BSA-IGFBP-1(Insulin-like growth factor binding protein 1) with anti-Hapten antibody. The hapten hapten-carrier conjugates BSA-IGFBP-1(Insulin-like growth factor binding protein 1) had been validated with our anti-Hapten antibody Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


OVA-IGFBP-1(Insulin-like growth factor binding protein 1)

Cat No.GMP-SMT-196-Ag-2
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Products descriptionCompetitive immunoassay-validated hapten-carrier conjugates OVA-IGFBP-1(Insulin-like growth factor binding protein 1) with anti-Hapten antibody. The hapten hapten-carrier conjugates OVA-IGFBP-1(Insulin-like growth factor binding protein 1) had been validated with our anti-Hapten antibody Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-IGFBP-1(Insulin-like growth factor binding protein 1) mouse monoclonal antibody

Cat No.GMP-SMT-196-Ab-1
Host of AntibodyMouse IgG
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)/
Products descriptionThe anti-Hapten antibody against hapten IGFBP-1(Insulin-like growth factor binding protein 1) had been validated with our hapten hapten-carrier conjugates BSA-IGFBP-1(Insulin-like growth factor binding protein 1) via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Anti-IGFBP-1(Insulin-like growth factor binding protein 1) human monoclonal antibody

Cat No.GMP-SMT-196-Ab-2
Host of AntibodyHuman IgG1
Bioactivity validationCompetitive immunoassay validation (Competitive ELISA) with hapten-carrier conjugates and anti-Hapten antibody;
Lateral flow immunoassay (LFIA);
ELISA IC50 (ppb)/
Products descriptionThe anti-Hapten antibody against hapten IGFBP-1(Insulin-like growth factor binding protein 1) had been validated with our hapten hapten-carrier conjugates BSA-IGFBP-1(Insulin-like growth factor binding protein 1) via competitive ELISA test.
ApplicationELISA tests and other immunoassays;
Lateral flow immunoassay (LFIA);
LTIA
Immunonephelometry
Time-resolved Fluorescence Immunoassay (TRFIA)
FormulationLyophilized from sterile PBS, PH 7.4
StorageStore at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.


Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Biomarker Information


    1. IGFBP-1 (Insulin-like Growth Factor Binding Protein 1) occupies a central role in the intricate web of signaling molecules that constitute the Insulin-like Growth Factor (IGF) system. This system is pivotal in orchestrating cell growth, proliferation, and differentiation. IGFBP-1's primary function revolves around its ability to interact with a high degree of specificity and affinity with IGF-1 and IGF-2, the principal members of the IGF family. This interaction effectively modulates the bioavailability and activity of these growth factors. Within the realm of in vitro diagnosis (IVD), IGFBP-1 emerges as a compelling biomarker with multifaceted applications.

    - Cancer Research (1): IGFBP-1 has emerged as a candidate biomarker in various cancers, including prostate and breast cancer. Elevated or diminished levels of IGFBP-1 in patient samples have been correlated with cancer presence, stage, and prognosis. Researchers and clinicians alike harness IGFBP-1 measurements to facilitate early cancer detection and prognostic assessment.

    - Growth Disorders (2): IGFBP-1 plays a significant role in growth regulation. Aberrations in IGFBP-1 levels have been associated with growth disorders in both pediatric and adult populations. These disorders encompass conditions such as gigantism, acromegaly, and growth hormone deficiency. Quantifying IGFBP-1 levels aids in the diagnosis and ongoing management of these conditions, enabling tailored therapeutic interventions.

    - Metabolic Disorders (3): Metabolic diseases, including type 2 diabetes mellitus and obesity, are intricately linked to IGFBP-1. IGFBP-1 is implicated in insulin sensitivity and glucose homeostasis. Its measurement can provide valuable insights into an individual's risk of developing metabolic disorders and the progression of existing conditions.

    - Pregnancy Monitoring (4): During pregnancy, IGFBP-1 takes on a unique role. IGFBP-1 levels in amniotic fluid can serve as an indicator of fetal well-being. Elevations in IGFBP-1 levels may signify fetal distress, prompting timely medical intervention to safeguard both maternal and fetal health.

    - Endocrine Pathologies (5): IGFBP-1 measurements find clinical utility in the realm of endocrine disorders. Disturbances in IGFBP-1 levels are often associated with conditions such as polycystic ovary syndrome (PCOS) and Cushing's syndrome. These measurements contribute to the precise diagnosis and management of endocrine pathologies.

    2. The measurement of IGFBP-1 (Insulin-like Growth Factor Binding Protein 1) assumes paramount importance in scientific research and clinical practice, driven by the following multifaceted considerations:

    - Disease Diagnostics (1): IGFBP-1 quantification represents a pivotal diagnostic tool for a broad spectrum of diseases, including cancers, growth disorders, and metabolic maladies. Timely and accurate diagnosis forms the bedrock of effective therapeutic strategies and patient care. For instance, in prostate cancer, elevated IGFBP-1 levels have been correlated with the presence of aggressive tumors, aiding in the stratification of patients for tailored treatments.

    - Treatment Monitoring (2): Monitoring the dynamic fluctuations in IGFBP-1 levels facilitates the ongoing assessment of treatment efficacy. This applies across diverse therapeutic modalities, ranging from cancer therapies, where changes in IGFBP-1 levels can indicate treatment response or resistance, to growth disorders, where IGFBP-1 measurements guide the optimization of growth hormone replacement therapies.

    - Risk Stratification (3): IGFBP-1 measurements extend their utility to the stratification of individuals at heightened risk of specific diseases. This enables the implementation of preemptive healthcare measures and personalized preventive interventions. In metabolic diseases such as type 2 diabetes, the assessment of IGFBP-1 levels aids in identifying individuals at increased risk due to insulin resistance.

    - Scientific Research (4): IGFBP-1 serves as a fertile ground for scientific exploration, particularly within the realms of oncology, endocrinology, and reproductive health. Its quantification in experimental paradigms contributes to a nuanced understanding of disease mechanisms and potential therapeutic avenues. Researchers leverage IGFBP-1 measurements to elucidate the intricate interplay between the IGF system and various diseases.

    - Pregnancy Surveillance (5): In the specialized context of pregnancy, the monitoring of IGFBP-1 levels assumes a critical role in ensuring the well-being of both the maternal and fetal entities. Deviations from the norm in IGFBP-1 concentrations can serve as early indicators of potential complications, necessitating timely medical interventions to safeguard pregnancy outcomes.

    In summation, IGFBP-1's measurement transcends disciplines, facilitating disease diagnosis, treatment assessment, risk stratification, scientific inquiry, and maternal-fetal health monitoring within the purview of in vitro diagnosis (IVD) and biomedical research. This multifaceted biomarker continues to unveil its potential in diverse facets of healthcare and scientific exploration, making it an indispensable component in the armamentarium of modern medicine.



    About GDU


    GDU

    GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.